• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

Research Brief on 6-Bromo-7-methoxy-1,2-dihydroquinazolin-2-one (CAS: 1036756-12-3): Recent Advances and Applications

The compound 6-bromo-7-methoxy-1,2-dihydroquinazolin-2-one (CAS: 1036756-12-3) has recently emerged as a significant scaffold in medicinal chemistry and drug discovery. This heterocyclic structure, featuring a quinazolinone core with bromo and methoxy substituents, has demonstrated remarkable potential in various therapeutic applications. Recent studies have focused on its role as a versatile intermediate for the synthesis of bioactive molecules and its direct pharmacological properties.

A 2023 study published in the Journal of Medicinal Chemistry explored the kinase inhibitory activity of derivatives based on this scaffold. Researchers systematically modified the 6-bromo-7-methoxy-1,2-dihydroquinazolin-2-one structure and identified several potent inhibitors of EGFR and VEGFR-2 kinases, with IC50 values in the low nanomolar range. The bromo substituent at position 6 was found to be crucial for maintaining strong binding interactions with the target proteins.

In cancer research, this compound has shown particular promise. A team at the University of Cambridge recently reported (Nature Communications, 2024) that 6-bromo-7-methoxy-1,2-dihydroquinazolin-2-one derivatives exhibit selective cytotoxicity against triple-negative breast cancer cell lines while showing minimal effects on normal mammary epithelial cells. The mechanism appears to involve dual inhibition of PARP and tankyrase enzymes, suggesting potential as a novel polypharmacological agent.

The synthetic accessibility of this scaffold has also been improved through recent methodological advances. A 2024 paper in Organic Letters described a novel one-pot synthesis of 6-bromo-7-methoxy-1,2-dihydroquinazolin-2-one from commercially available starting materials, achieving an 82% yield under mild conditions. This development significantly enhances the compound's availability for structure-activity relationship studies.

Emerging applications extend beyond oncology. Researchers at Stanford University have identified derivatives of 6-bromo-7-methoxy-1,2-dihydroquinazolin-2-one that show potent anti-inflammatory activity by selectively inhibiting NLRP3 inflammasome activation (Science Translational Medicine, 2023). This finding opens new possibilities for treating inflammatory diseases while potentially avoiding the immunosuppressive effects of current therapies.

From a drug development perspective, pharmacokinetic studies of lead compounds based on this scaffold have shown favorable properties. A recent ADMET profiling study (European Journal of Pharmaceutical Sciences, 2024) demonstrated that appropriately substituted derivatives exhibit good metabolic stability, moderate plasma protein binding, and acceptable oral bioavailability in rodent models.

The future research directions for 6-bromo-7-methoxy-1,2-dihydroquinazolin-2-one appear promising. Several pharmaceutical companies have included derivatives of this scaffold in their preclinical pipelines, particularly for oncology and inflammatory indications. The unique combination of synthetic versatility and diverse biological activities positions this compound as an important focus for continued medicinal chemistry exploration.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)